Bioequivalence study of two different clopidogrel bisulfate film-coated tablets

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 6, 2009, Pages 297-302

  Richter, Wolfram ^a,e   Erenmemisoglu, Aydin ^b   Van Der Meer, Mike John ^c   Emritte, Nizam ^d   Tuncay, Emine ^d   Koytchev, Rossen ^a  

^a Cooperative Clinical Drug Research and Development AG ^*  (Germany)

^b ERCIYES UNIVERSITY   (Turkey)

^c Trident Bioanalytics Ltd   (Ireland)

^d Drogsan Pharmaceuticals   (Turkey)

^e CCDRD AG   (Germany)

Author keywords

CAS 113665 84 2; Clopidogrel, bioequivalence, clinical pharmacokinetics, highly variable drug, replicate trial design; Platelet aggregation inhibitors

Indexed keywords

CLOPIDOGREL;

ADULT; ANUS PRURITUS; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SOLUBILITY; FATIGUE; FILM COATING; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SNEEZING; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 68549125293     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296400     Document Type: Article

References (13)

1. Prescribing Information Plavix®. USA: Bristol-Myers Squibb/Sanofi Pharmaceuticals; Jan 2005.
2. Plosker GL, Lyseng-Williamson KA. Clopidogrel: A Review of its Use in the Prevention of Thrombosis. Drugs. 2007; 67(4):613-646 (Pubitemid 46442637)
3. ICH Topic E 6. Guideline for Good Clinical Practice. Step 5, Consolidated Guideline from 01. 05. 1996. Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95). Jan. 1997.
4. Heinzel G, Woloszczak R, Thomann (eds.). TopFit 2.0, pharmacokinetic and pharmacodynamic data analysis system for the PC. Stuttgart: Gustav Fischer; 1993.
5. Questions & Answers on the Bioavailability and Bioequivalence Guideline (EMEA/CHMP/EWP/40326/2006).
6. CPMP Draft Guideline On The Investigation Of Bioequivalence. (CPMP/EWP/QWP/1401/98 Rev. 1); July 2008.
7. Hauschke D, Steinijans VW, Diletti E. A distribution free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990;28(2):72-78 (Pubitemid 20098974)
8. Amidon GL, Lennernas H, Shah VP, Crison JR. A Theoretical basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability. Pharm. Res. 1995;12:413-420
9. Nirogi RV, Kandikere VN, ShuklaM, Mudigonda K, Maurya S, Boosi R. Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006;20(11):1695-1700 (Pubitemid 43793870)
10. Slugg PH, Much DR, Smith WB, Vargas R, Nichola P, Necciari J. Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel. J Clin Pharmacol. 2000;40(4):396-401.
11. Shin BS, Yoo SD. Determination of clopidogrel in human plasma by liquid chromatography/tandem mass spectrometry: application to a clinical pharmacokinetic study. Biomed Chromatogr. 2007;21(9):883-889 (Pubitemid 47272324)
12. Lainesse A, Ozalp Y, Wong H, Alpan RS. Bioquivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung. 2004;54(9 a):600-604 (Pubitemid 39278902)
13. Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 1999;25(Suppl. 2): 25-28